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To understand whether the presence of cold reactive lymphocytotoxic antibodies (LCA) (reactive at
15°C) in the system has any effect on immunity to tuberculosis lymphocytotoxic antibodies to adherent
cells (enriched-B ceils) and non-adherent cells were studied in active-TB (n=42) and inactive-TB (cured)
patients (n=49) and healthy controls (n=32). The plasma samples of inactive-TB patients showed higher
percentage of positivity for lymphocytotoxic antibodies (36.7%) than the active-TB patients (21.4%) and
control subjects (18.8%). No significant difference on antibody and lymphocyte response against
Mycobacterium tuberculosis culture filtrate antigens was observed between LCA positive and LCA
negative active-TB patients and normal healthy controls. Further, determinationof HLA-DR phenotype
of the patients and control subjects showed that individuals positive for lymphocytotoxic antibodies
were more among HLA-DR2 positive and DR7 positive active-TB patients and control subjects than
non-DR2 and non-DR7 subjects. The present study suggests that the cold reactive lymphocytotoxic
antibodies may be against B-lymphocytes and persistent for a longer time. HLA-DR2 and -DR7 may be
associated with the occurrence of LCA activity. Further, the presence of LCA has no immunoregulatory
role on immunity to tuberculosis.
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Lymphocytotoxins or lymphocytotoxic antibodies
(LCA) are complement-binding antibodies that can
occur in healthy individuals following viral or
bacterial infections and after immunization or
vaccination1. These antibodies have been shown in
the sera of patients suffering from viral diseases2 and
also occur in several autoimmune diseases,
malignancies and immunological diseases in which
viral infection is implicated3-6. These
lymphocytotoxic antibodies include both cold-
reacting (IgM; react at 15°C) and warm reacting-
antibodies (IgG; react at 37°C). Cold-reactive
lymphocytotoxic antibodies have been found in non-
viral infectious diseases such as tuberculosis1,7 and
leprosy8-11. Warm reacting antibodies have been
shown to react with the major subsets of T-cells4,6.
Lymphocytotoxic antibodies directed towards
5
specific T cell subsets have been reported in systemic
lupus erythematosis (SLE)12. LCA activity in a number
of auto-immune conditions, especially SLE and
rheumatoid arthritis has been reported to be directed
against T-lymphocyte subpopulation12,13. An
immunoregulatory role for these antibodies has been
p o s t u l a t e d .
Although the biological stimulus for LCA
production is not clearly understood, evidences
indicate that anti-B cell LCAs are autoantibodies
directed against self IgM14-16. The association of LCA
with particular HLA-DR antigen has been studied in
autoimmune diseases5,17,18. In mycobacterial
diseases, most of the studies on LCA have been
carried out in leprosy8-11,16 with less attention being
paid to tuberculosis1,7,19,20. Further, the
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immunoregulatory role of these antibodies on the
immunity to tuberculosis has not been explored. The
present study was carried out to understand whether
the presence of LCA in the system has an
immunoregulatory effect  on ant ibody and
lymphocyte response to Mycobacterium tuberculosis
culture filtrate antigen in patients with active and
inactive tuberculosis and normal healthy control.
Further, the influence of HLA-DR antigen on the
occurrence of these antibodies in pulmonary
tuberculosis has also been studied.
Material & Methods
Study subjects: 
(i) Active tuberculosis (ATB) patients - Patients
attending the Tuberculosis Research Centre (TRC),
Chennai, with respiratory symptoms and radiographic
abnormalities suggestive of pulmonary TB were
studied. These patients had sputum positive for M.
tuberculosis by. smear and culture. Blood samples
were taken before the start of chemotherapy. Among
the 42 ATB patients studied, there were 36 males and
6 females. The mean age (with SE) was 40.1±6.7 for
males and 26.8±2.2 for females.
(ii) Inactive tuberculosis (ITB) patients (cured
patients) – Patients classified as suffering from
active pulmonary tuberculosis had received 10-15 yr
earlier, a short course chemotherapy for 6-8 months
at the TRC. At the time of blood sample collection all
these cured patients were in the quiescent stage of the
disease. Of the 49 cured patients studied, 42 were
males and 7 were females. The mean age (with SE)
was 38±1.4 for males and 39.9±4.9 for females.
(iii) Controls – Spouses of cured TB patients
living together for 10-15 yr (family contacts; n=5)
and clinicians, social workers, health visitors,
laboratory volunteers and other staff (n=27) working
at TRC for more than 3 years were studied. Among
the 32 control subjects studied, 15 were males and 17
were females. The mean age (with SE) was 40.8±2.3
for males and 37.9±2.2 for females. All the family
contacts and other control subjects were clinically
normal at the time of blood sample collection.
The patients and spouses were not consanguineous
to each other. The other control subjects were not
related to any of the patients. The patients and the
controls were a randomly selected population
belonging to the same ethnic origin. They were Tamil
speaking south Indian population (belonging to
different communities) living in and around Chennai.
This study was carried out during January to
December 1995 at the Tuberculosis Research Centre,
Chennai.
Peripheral blood : Peripheral blood mononuclear
cells (PBMC) were separated from heparinised (20
units/ml) blood samples using Ficoll-hypaque density
gradient centrifugation21. Plasma was used for
antibody titre against M. tuberculosis and
lymphocytotoxic antibodies. PBMC was used for
lymphocytotoxin assay, HLA typing and lymphocyte
response.
Lymphocytotoxic antibody (lymphocytotoxin) assay:
The method described for serological determination
of HLA has been used22. Briefly, plasma samples of
patients as well as the controls were coated in Terasaki
microtiter plates (Nunc, Denmark). Nylon wool
column separated non-adherent (enriched T cell
population) and adherent (enriched B cell population)
cells (allogenic cells) were used as target cells. The
non-adherent and adherent cells (2000 cells per well)
were added to each well and incubated for 1 h at
15°C. Rabbit complement (5 µl/well) was added and
incubated further for 2 h at 15°C. The dead cells were
stained with 5 µl eosin (3%) and fixed in neutralised
formalin. The plates were read in an inverted phase
contrast microscope (Leitz, Portugal) at 160 x
magnification. The cytotoxicity was assessed by
scoring the reactions as 2, 4, 6 and 8 depending on the
percentage of cytotoxicity as 11-20 per cent = 2; 21-
40 per cent = 4; 41-80 per cent = 6; and 81-100 per
cent = 8. A score of 6 and above was taken as a
positive reaction for cytotoxic antibody. Plasma
reacting against lymphocytes of three different
subjects and above were considered as positive.
HLA typing : Serological determination of HLA-DR
antigens was carried out in ATB and ITB patients and
control subjects using nylon wool-adherent
peripheral blood mononuclear cells (enriched B
lymphocytes) by standard microlymphocytotoxicity
assay22.
Antibody and lymphocyte response to M. tuberculosis
culture filtrate antigen : M. tuberculosis culture filtrate
antigen was prepared and used. The IgG antibody
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titre against M. tuberculosis culture filtrate antigens to M. tuberculosis antigen (1 and 10 µg doses) was
was measured by ELISA. Lymphoproliferative seen in LCA positive tuberculosis patients than LCA
response of the patients and control subjects to M. negative ATB patients (Table II). However, this trend
tuberculosis culture filtrate antigen (10 µg/ml) was was not significant. No such trend was seen in control
studied23. subjects.
Statistical analysis : The frequency of HLA-DR
antigens was calculated by direct allelic count. The
level of significance of presence of lymphocytotoxic
antibodies was ascertained by proportionality test
and Student’s ‘t’ test for antibody titre and lymphocyte
response. Results are expressed as arithmetic mean ±
standard error (SE).
Results
Among the subjects positive for lymphocytotoxins,
an increased percentage of active TB patients with
HLA-DR2 (55.6%) and HLA-DR7 (55.6%) were
positive for lymphocytotoxic antibodies when
compared to other DR antigens (Table III). However,
in the DR6 positive active TB group, 44.4 per cent
(4/9) of the patients were positive for lymphocytotoxic
antibodies. Among the four patients three were DR6/
DR7 positive heterozygotes.
Lymphocytotoxic antibodies against allogenic
lymphocytes were seen in active and cured pulmonary
tuberculosis patients as well as normal healthy control
subjects. A significantly higher percentage of ITB
patients were positive for lymphocytotoxic antibodies
than ATB patients and controls (P <0.05). Whereas,
no difference was seen between ATB patients and
controls (Table I). Plasma samples of active-TB,
inactive-TB and control subjects reacted with nylon
wool adherent cell population (enriched B-cell).
These lymphocytotoxic antibodies were not against
HLA antigens as judged by a panel of HLA typed
cells (data not shown).
Discussion
Presence of lymphocytotoxic antibodies in the
system did not show any effect on antibody titre to M.
tuberculosis antigens in LCA positive active-TB
patients as well as control subjects than LCA negative
patients and controls. However, a trend towards a
decreased lymphocyte response (stimulation index)
In the present study, ATB and ITB patients as well
as healthy controls showed lymphocytotoxic
antibodies to allogenic mononuclear cells. These
antibodies may be developed against self antigens
(autoantigens) or antigens of M. tuberculosis origin,
which may have structural similarity with self
antigen .    19 During the active stage of the disease as
well as during treatment with anti-TB drugs, the
cellular components such as DNA and other nuclear/
cellular proteins of the infected/lysed cells of the
tissues, at the site of infection, may be exposed to the
immune system which leads to autoantibody
production. Under in vivo condition such antibodies
may be reactive against the cell surface determinants
of nucleated cells which may be involved in cell
death either due to autoantibody and complement
mediated cytotoxicity or cell necrosis or apoptosis.
Table I. Presence of Iymphocytotoxic antibodies in control subjects, active-TB (ATB) and inactive-TB (ITB) patients to allogenic lymphocytes
Study subjects No. of % of plasma Positive for Positive for Positive for
plasmatested positive for LCA NA only A only NA and A
Controls 32 18.8 0
(n=6)
ATB 42 21.4 0
(n=9)
ITB 49 36.7*+ 0
(n=18)
LCA, lymphocytotoxic antibodies; NA, non-adherent cell population; A. adherent cell population
P < 0.05* as compared to controls and + ATB
6 0
4 5
17 1
Table III. Influence of HLA-DR on lymphocytotoxic antibodies
(LCA)
HLA-DR Controls ATB ITB
(n=6) (n=9) (n=18)
DR1+
DR1-
DR2+
DR2-
DR3+
DR3-
DR4+
DR4-
DR5+
DR5-
DR6+
DR6-
DR7+
DR7-
DR8+
DR8-
DR9+
DR9-
DR10+
DR10-
1(16.7)
5 (83.3)
3 (50)
3 (50)
1 (16.7)
5 (83.3)
1 (16.7)
5 (83.3)
1 (16.7)
5 (83.3)
1 (16.7)
5 (83.3)
3 (50)
3 (50)
0 (0)
6 (100)
0 (0)
6 (100)
1 (16.7)
5 (83.3)
0 (0)
9 (100)
5 (55.6)
4 (44.6)
0 (0)
9 (100)
1 (11.1)
8 (88.9)
2 (22.2)
7 (77.8)
4 (44.4)
5 (55.6)
5 (55.6)
4 (44.4)
1 (11.1)
8 (88.9)
0 (0)
9 (100)
0 (0)
9 (100)
2 (11.1)
16 (88.9)
8 (44.4)
10 (55.6)
6 (33.3)
12 (66.7)
5 (27.8)
13 (72.2)
4 (22.2)
14 (77.8)
2 (11.1)
16 (88.8)
5 (27.8)
13 (72.2)
0 (0)
18 (100)
0 (0)
18 (100)
4 (22.2)
14 (77.8)
n, no. of individuals positive for lymphocytotoxic antibodies
Figures in parentheses are the percentage values
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Table II. Comparison of antibody titres and lymphocyte response to M. tuberculosis culture filtrate antigen in LCA positive and LCA negative
patients and controls
LCA positive LCA negative
Subjects
Antibody Lymphocyte response in Antibody Lymphocyte response in
titre stimulation index. titre stimulationindex,
SI SI
M.tb Ag. µg/ml M.tb Ag, µg/ml
0.1 1.0 10.0 0.1 1.0 10.0
Control 400.0±182.4 4.2±1.1 12±6 15.9±5.7 451.6±142.4 3.8±0.9 8.1±1.6 18.6±3.2
(n=25) (6)                (5) (5) (5) (19) (19) (19) (19)
Active-TB 2720.0±1065.3 1.4±1.2 2.2±0.5 4.0±0.7 2316.5±538.8 1.6±0.2 3.4±0.8 6.8±1.9
(n=32) (9) (7) (7) (7) (23) (23) (23) (23)               
LCA, lymphocytotoxic antibody; M.tb Ag, M. tuberculosis culture filtrate antigen
Figures in the parentheses represent the number of patients or control subjects studied
Most of the LCA positive plasma samples of the
patients and control subjects reacted against adherent
cells (enriched B cells). This shows that the antibodies
reacting at 15°C may be against B-lymphocytes.
Many studies carried out in leprosy patients revealed
that most of these antibodies are cold reactive (react
at 15°C) and developed against B-lymphocyte8-11,16.
Further, it has been shown that these LCA have
developed against surface IgM (immunoglobulin) of
B-cells8-11,14,15.
A higher percentage of inactive-TB patients
showed LCA activity against enriched B-cells. These
ITB (quiescent) patients even 10 to 15 yr after
treatment showed lymphocytotoxic antibodies. This
shows the persistence of memory B-cells which may
be involved in the production of lymphocytotoxic
antibodies and it may persist for a longer time.
Presence of LCA in the system showed no dramatic
effect on the immunity to tuberculosis. However, a
trend towards a decreased lymphocyte response to
M. tuberculosis antigens (10 µg) was seen in active-
TB patients. This inhibitory/regulatory effect may be
due to anti-idiotypic antibodies, which may be
produced against autoantibodies. However, further
studies are required to substantiate these preliminary
data.
Among the LCA positive subjects (patients and
controls) more number of HLA-DR2 and DR7
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positive control subjects, active-TB and inactive-TB
patients were seen. This suggests that HLA-DR2 and
DR7 may enhance the production of lymphocytotoxic
antibodies. An association between lymphocytotoxic
antibodies and HLA-DR2 has also been reported in
rheumatoid arthritis18. An increased anti-F (ab’)2 IgG
auto-antibodies has been shown in HLA-DR2 positive
pulmonary-TB patients as compared to -DR2 negative
patients .20 Our recent study of pulmonary tuberculosis
patients revealed that HLA-DR2 is associated with
increased antibody response and decreased
lymphocyte response to M. tuberculosis 23. Moreover,
patients positive for HLA-DR2/DR7 heterozygous
combination also showed a higher antibody
production24. Since, HLA-DR2 is associated with far
advanced smear positivity cases of pulmonary TB
than with cases of minimal and moderate radiographic
lung lesions25 and extensive disease with drug failure
cases26, augmentation of the production of
lymphocytotoxic antibodies by HLA-DR2 and DR7
may further damage the cells and tissues of the lung
which will be more detrimental to the host.
The present study suggests that lymphocytotoxic
antibodies may occur during the active stage of
tuberculosis. Persistence of LCA activity during the
quiescent stage of the disease is evident. The
occurrence of these antibodies may be associated
with HLA-DR2 and DR7. LCA may play a role in the
pathogenesis of tuberculosis.
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